Paul Getz, MD

Dundee Dermatology. 1201 Water Tower Road. West Dundee IL. 60118-3330
T 847.851.8888 F 847.851.8889

profile

Over three decades of experience in multiple facets of dermatology; medical, surgical, and aesthetic.

experience

Medical Director, **Dundee Dermatology**
1201 Water Tower Road; West Dundee, Illinois — May, 2003-present

Associate Physician, **Leone Dermatology Center**
3060 N Arlington Heights Road; Arlington Heights, IL — June, 1999-2003

Staff Physician, **Medical Arts Associates**
Moline, Illinois — Oct, 1997-June, 1999

Senior Physician, **The Permanente Medical Group**
Richmond, California — January, 1982-1997

appointments

Chief, Department of Dermatology
Kaiser Foundation Hospital, Richmond Medical Center
Richmond, California — 1988-1997

Clinical Instructor
Department of Dermatology
University of California, San Francisco — 1982-1995

Staff President — 1989–1990
Staff Vice President — 1987–1988
Kaiser Foundation Hospital, Richmond Medical Center

Chief Resident in Dermatology
Cook County Hospital, Chicago — 1980-1981

certification	**Diplomate**, American Board of Dermatology	1981
	Recertified, American Board of Dermatology	2009
education	**Doctor of Medicine**, University of Illinois, Chicago	1977
	Bachelor of Science, University of Illinois, Urbana	1970
training	**Residency**, **Dermatology**; Cook County Hospital, Chicago	1981
	Rotating Internship; Cook County Hospital, Chicago	1978

affiliations

Fellow, American Academy of Dermatology
Fellow, American Society for Dermatologic Surgery
Fellow, American Society for Laser Medicine and Surgery
Member, Chicago Dermatologic Society

clinical research as principal investigator:

05/2015 – present	phase 3: multicenter, randomized, double-blind, parallel-group, study followed by a dose-blind period and all open-label follow-up to evaluate the efficacy and safety of certolizumab pegol in subjects with moderate to severe chronic plaque psoriasis
02/2015 – 09/2015	phase 2: randomized, double-blind, placebo-controlled study to evaluate safety and efficacy of pf-04965842 in subjects with moderate to severe psoriasis
12/2014 – present	phase 3: randomized, double-blind, placebo-controlled study to demonstrate the efficacy and long term safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis
08/2014– present	phase 3: randomized, double-blind, multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar adalimumab and humira in patient with moderate to severe chronic plaque-psoriasis

clinical research as principal investigator:

03/2013 – present	phase 3: randomized, placebo-controlled, parallel design study to evaluate the efficacy and safety/tolerability of subcutaneous SCH 900222/MK-3222, followed by an optional long-term safety extension study, in subjects with moderate-to-severe chronic plaque psoriasis
08/2012 – 11/2015	phase 3: study to evaluate the efficacy, safety, and effect of withdrawal and retreatment with brodalumab in subjects with moderate to severe plaque psoriasis
05/2011 – present	phase 3: multi-site, open-label study of the long term safety and tolerability of 2 oral doses of tofacitinib in subjects with moderate to severe chronic plaque psoriasis
02/2011 – 09/2015	phase 3: multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of apremilast in subjects with moderate to severe plaque psoriasis
08/2013 – 12/2014	phase 2b: multi-site, randomized, double-blind, vehicle-controlled, parallel-group study of the efficacy, safety, local tolerability and pharmacokinetics of 2 dose strengths and 2 regimens of tofacitinib ointment in subjects with chronic plaque psoriasis.
07/2013 – 12/2014	phase 2a: randomized, double-blind, placebo-controlled, multicenter study to assess MEDI8968 in hidradenitis suppurativa
07/2011 – 12/2013	phase 3, multi-site, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of 2 oral doses of tofacitinib in subjects with moderate to severe chronic plaque psoriasis
06/2010 – 04/2011	phase 2: dose ranging and efficacy study of ixekizumab (an anti-il-17 antibody) in patients with moderate-to-severe psoriasis
01/2009 – 12/2010	phase 3: efficacy and safety of alitretinoin in the treatment of severe chronic hand eczema refractory to topical therapy
06/2008 – 08/2009	phase 2b: multicenter, randomized, double-blind, parallel-group, placebo-controlled trial evaluating the efficacy and safety of dose regimens with oral tofacitinib in the treatment of subject with chronic plaque psoriasis
05/2008- 06/2009	phase 3: 12-week double-blind, multi-center, randomized study designed to evaluate the efficacy and safety of briakinumab versus Enbrel versus placebo in the treatment of moderate to severe plaque psoriasis

clinical research as principal investigator:

02/2008 – 11/2011	open registry: multicenter, patients with psoriasis who are candidates for systemic therapy including biologics
02/2008 – 08/2009	phase 3: multicenter, randomized, double-blind, placebo-controlled study comparing the safety and efficacy of two dosing regimens of briakinumab to placebo in subjects with moderate to severe chronic plaque psoriasis
08/2007 – 02/2012	phase 3: multicenter, open-label study to assess the efficacy and safety of infliximab therapy in patients with plaque psoriasis who had an inadequate response to Enbrel
12/2006 – 04/2007	phase 4: clinical evaluation of clenziderm for the topical treatment of patients with mild to moderate facial acne vulgaris
04/2007 – 10/2007	phase 3: randomized, double-blind, placebo-controlled, parallel design, multi-site clinical study to evaluate the Bioequivalence of calcipotrene ointment 0.005% to DOVONEX® 0.005% in patients with moderate to severe plaque psoriasis
02/2004 - 10/2004	phase 3: multicenter, open label, prospective study to evaluate the effectiveness and safety of etanercept in the treatment of subjects with psoriasis.
06/2003 – 06/2004	phase 4: assessment and tracking of long-term alefacept (LFA-3/IgG1 fusion protein) safety
09/2003- 04/2004	phase 3: multicenter, open-label to observe effect of etanercept on joint and skin disease in subjects with psoriatic arthritis
09/2003 - 05/2004	phase 3b: open-label, multicenter study to evaluate the safety of 1.0-mg/kg subcutaneously administered efalizumab in adults with moderate to severe plaque psoriasis, including those who are receiving concomitant antipsoriatic therapies or have recently transitioned from systemic therapies.